170 related articles for article (PubMed ID: 21385704)
1. Cancer. New epigenetic drivers of cancers.
Elsässer SJ; Allis CD; Lewis PW
Science; 2011 Mar; 331(6021):1145-6. PubMed ID: 21385704
[No Abstract] [Full Text] [Related]
2. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
Jiao Y; Shi C; Edil BH; de Wilde RF; Klimstra DS; Maitra A; Schulick RD; Tang LH; Wolfgang CL; Choti MA; Velculescu VE; Diaz LA; Vogelstein B; Kinzler KW; Hruban RH; Papadopoulos N
Science; 2011 Mar; 331(6021):1199-203. PubMed ID: 21252315
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours.
Pipinikas CP; Dibra H; Karpathakis A; Feber A; Novelli M; Oukrif D; Fusai G; Valente R; Caplin M; Meyer T; Teschendorff A; Bell C; Morris TJ; Salomoni P; Luong TV; Davidson B; Beck S; Thirlwell C
Endocr Relat Cancer; 2015 Jun; 22(3):L13-8. PubMed ID: 25900181
[No Abstract] [Full Text] [Related]
4. Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors.
Capurso G; Archibugi L; Delle Fave G
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):594-601. PubMed ID: 25619712
[TBL] [Abstract][Full Text] [Related]
5. Ileal neuroendocrine tumors show elevated activation of mammalian target of rapamycin complex.
Geis C; Fendrich V; Rexin P; Di Fazio P; Bartsch DK; Ocker M; Quint K; Heverhagen AE
J Surg Res; 2015 Apr; 194(2):388-393. PubMed ID: 25439321
[TBL] [Abstract][Full Text] [Related]
6. Current understanding of the molecular biology of pancreatic neuroendocrine tumors.
Zhang J; Francois R; Iyer R; Seshadri M; Zajac-Kaye M; Hochwald SN
J Natl Cancer Inst; 2013 Jul; 105(14):1005-17. PubMed ID: 23840053
[TBL] [Abstract][Full Text] [Related]
7. The genetics of neuroendocrine tumors.
Öberg K
Semin Oncol; 2013 Feb; 40(1):37-44. PubMed ID: 23391111
[TBL] [Abstract][Full Text] [Related]
8. Tumor suppressor functions of DAXX through histone H3.3/H3K9me3 pathway in pancreatic NETs.
Ueda H; Akiyama Y; Shimada S; Mogushi K; Serizawa M; Matsumura S; Mitsunori Y; Aihara A; Ban D; Ochiai T; Kudo A; Tanabe M; Tanaka S
Endocr Relat Cancer; 2018 Jun; 25(6):619-631. PubMed ID: 29599123
[TBL] [Abstract][Full Text] [Related]
9. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J
Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320
[TBL] [Abstract][Full Text] [Related]
10. Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system.
Arnold CN; Sosnowski A; Schmitt-Gräff A; Arnold R; Blum HE
Int J Cancer; 2007 May; 120(10):2157-64. PubMed ID: 17278096
[TBL] [Abstract][Full Text] [Related]
11. KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors.
Yuan F; Shi M; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Int J Biol Sci; 2014; 10(9):957-65. PubMed ID: 25210493
[TBL] [Abstract][Full Text] [Related]
12. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
[TBL] [Abstract][Full Text] [Related]
13. NETs: organ-related epigenetic derangements and potential clinical applications.
Cives M; Simone V; Rizzo FM; Silvestris F
Oncotarget; 2016 Aug; 7(35):57414-57429. PubMed ID: 27418145
[TBL] [Abstract][Full Text] [Related]
14. Releasing the brakes on a chromatin-remodeling enzyme.
Manning BJ; Peterson CL
Nat Struct Mol Biol; 2013 Jan; 20(1):5-7. PubMed ID: 23288358
[TBL] [Abstract][Full Text] [Related]
15. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
Park JK; Paik WH; Lee K; Ryu JK; Lee SH; Kim YT
Oncotarget; 2017 Jul; 8(30):49796-49806. PubMed ID: 28591701
[TBL] [Abstract][Full Text] [Related]
16. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.
Hackeng WM; Brosens LA; Poruk KE; Noë M; Hosoda W; Poling JS; Rizzo A; Campbell-Thompson M; Atkinson MA; Konukiewitz B; Klöppel G; Heaphy CM; Meeker AK; Wood LD
Hum Pathol; 2016 Oct; 56():93-100. PubMed ID: 27342911
[TBL] [Abstract][Full Text] [Related]
17. Histone variants in pluripotency and disease.
Skene PJ; Henikoff S
Development; 2013 Jun; 140(12):2513-24. PubMed ID: 23715545
[TBL] [Abstract][Full Text] [Related]
18. PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors.
Ohki R; Saito K; Chen Y; Kawase T; Hiraoka N; Saigawa R; Minegishi M; Aita Y; Yanai G; Shimizu H; Yachida S; Sakata N; Doi R; Kosuge T; Shimada K; Tycko B; Tsukada T; Kanai Y; Sumi S; Namiki H; Taya Y; Shibata T; Nakagama H
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):E2404-13. PubMed ID: 24912192
[TBL] [Abstract][Full Text] [Related]
19. New players in heterochromatin silencing: histone variant H3.3 and the ATRX/DAXX chaperone.
Voon HP; Wong LH
Nucleic Acids Res; 2016 Feb; 44(4):1496-501. PubMed ID: 26773061
[TBL] [Abstract][Full Text] [Related]
20. A chromatin remodeling complex regulates topoisomerase IIα function.
Cancer Discov; 2013 Jul; 3(7):OF33. PubMed ID: 23847378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]